Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma

<div>Survival curves regarding overall survival and progression-free survival. The mean progression-free survival and overall survival were 21.6 ± 3.6 months (95% CI 14.5, 28.8 months) and 43.7 ± 5.8 months (95% CI 24.2, 56.0 months), respectively.</div>

Canadian Journal of Gastroenterology and Hepatology

fig3

Figure 3

Figure 3: Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 

Figure 3 | Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma 